Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.13102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, People's Republic of China.
Generalized Pustular Psoriasis (GPP) is a rare, severe, life-threatening form of psoriasis and often resistant to conventional systemic therapy. It can be induced by deficiency of interleukin (IL)-36 receptor antagonist. Treatment of patients with GPP is often difficult, and there is no consensus on the best options available to date.
View Article and Find Full Text PDFLong-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study.
J Dermatolog Treat
December 2025
Department of Dermatology, Children's Hospital Affiliated to Kunming Medical University, Kunming, China.
To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP). A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0-3 years received 75 mg of secukinumab, while those aged 3-12 years received 150 mg.
View Article and Find Full Text PDFCharacteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis Group.
Dermatol Ther (Heidelb)
December 2024
Department of Dermatology, Institute of Medical Sciences, Medical College of the University of Rzeszów, Rzeszów, Poland.
Article Synopsis
- The study aimed to analyze the demographic and clinical traits of Polish patients with generalized pustular psoriasis (GPP), revealing that most patients are middle-aged women with common comorbidities like hypertension and cardiovascular diseases.
- A total of 90 patients were examined, who had a median GPP duration of 3 years and experienced an average of 2 flares, often requiring hospitalization; main triggers for flares included medications and infections.
- The findings showed significant differences, such as younger patients often having GPP alongside psoriasis vulgaris (PV), highlighting a need for better management due to the high hospitalization rate and recurrent flares.
Exploring the Chronic Nature of Generalized Pustular Psoriasis [Podcast].
Clin Cosmet Investig Dermatol
November 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease characterized by persistent symptoms and sudden flares of painful, sterile pustules, and may be accompanied by systemic inflammation. Ongoing symptoms of GPP can have a serious impact on patient quality of life, morbidity, and mortality, and severe flares may be life-threatening if left untreated. Guidelines have been developed for the treatment of GPP flares; however, health care professionals and patients are lacking guidance on the management of long-term, persistent symptoms of GPP.
View Article and Find Full Text PDFSuccessful Treatment of Pediatric Generalized Pustular Psoriasis (GPP) with Spesolimab: 5 Case Reports and Evaluations of Circulating IL-36 Levels.
J Inflamm Res
November 2024
Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijng, People's Republic of China.
Article Synopsis
- Generalized pustular psoriasis (GPP) is a severe skin disease that can be life-threatening, and spesolimab is an IL-36 receptor antibody showing promise for treating it, especially in adults, though data for children are limited.
- The study involved five young patients (4-12 years old) who received a single dose of spesolimab, with significant improvements in their skin condition observed just one week later.
- All patients showed decreased levels of key inflammatory markers and no recurrence of symptoms was noted after treatment, suggesting that spesolimab could be a potential treatment option for children with GPP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!